Global Next-Generation Biologics Market 2016-2020
About Next-generation Biologics
According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a
"virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or
allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings."
Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or
derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or
arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or
condition. The differences between the small molecules and biologics includes the molecular weight, structure,
procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex
molecular structure. They are usually derived from living organisms, which is another important feature that
differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.
Publisher's analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the
period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for
2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-
generation biologics. The report also considers the revenues to be generated from the sales of drugs that are
expected to be launched into the market during the forecast period.
View Complete Report @ http://www.reportsweb.com/global-next-generation-biologics-market-
2016-2020
Contact Us : +91-20-67278686 | E-Mail : [email protected]